

DAFTAR PUSTAKA

- Ahmadi, S. 2008. *Faktor Risiko Kejadian Malaria di Desa Lubuk Nipis Kecamatan Tanjung Agung Kabupaten Muara Enim*. Tesis tidak diterbitkan. Semarang: Universitas Diponegoro.
- Alker, P.A., Mwapasa, V., Purfield, A., Rogerson, S.J., Molyneux, M.E., Kamwendo, D.D., Tadesse, E., Chaluluka, E., Meshnick, S.R. 2005. *Mutation Associated with Sulfadoxine-Pyrimethamine and Chlorproguanil Resistance in Plasmodium falciparum Isolates from Blantyre, Malawi*. Antimicrobial Agents and Chemotherapy. 49: 3919 -21.
- Aminake, M.N., Arndt, H-D., Pradel, G. 2012. *The Proteasome of Malaria Parasite: A Multi-stage Drug Target for Chemotherapeutic Intervention*. Germany : Elsevier Ltd.
- Brooks, F.B., Janet, S.B., & Stephen, A.M. 2004. *Jawetz, Melnick, and Adelberg's Medical Microbiology 23rd Edition*. New York: The McGraw Hill Companies, Inc.
- Ceylan, O., Gulten, O., dan Ugur, A. 2008. *Isolation of Soil Streptomyces as Sourceantibiotics Active against Antibiotic-resistant Bacteria*. EurAsian Journal of BioSciences EurAsia J BioSci 2: 73-82.
- Delcros, J.G., Floc'h, M.B., Prigent, C., Arlot-Bonnemains, Y. 2003. *Proteasome Inhibitor as Therapeutic Agents: Current and Feature Strategies*. France : Bentham Science Publishers Ltd.
- Depkes RI, 2008. *Epidemiologi Malaria di Indonesia*. Kementerian Kesehatan RI, Jakarta.
- Dong, M.W. 2013. *The Essence of Modern HPLC: Advantages, Limitations, Fundamentals, and Opportunities*. 31(6): 472-79
- Eugine, M.B. 2011. *Thin Layer Chromatography*. University Of Nairobi : Department Of Mechanical Engineering.
- Gamer, P., Graves, P.M. 2005. *The Benefits of Artemisinin Combination Therapy for Malaria Extend Beyond the Individual Patient*. DOI: 10.1371/journal.pmed.0020105.
- Gillespie, S & Richard, DP. 2001. *Principles and Practice of Clinical Parasitology*. London: John Wiley and Sons Ltd.
- Goodfellow, M, & Simpson, K.E. 1987. Ecology of Streptomycetes. Front. Appl. Microbiol, 2:97-125.
- Greenwood, B.M., Fidock, D.A., Kyle, D.E., Kappe, S.H.I., Alonso, P.L., Collins, F.H., Duffy, P.E. 2008. *Malaria: Progress, Perils, and Prospects for Eradication*, J Clin Invest.118 (4):1266–76
- Hasibuan, A.I.S. 2010. *Tingkat Pengetahuan Masyarakat terhadap Penyakit Malaria di Kecamatan Batang Serangan Kabupaten Langkat Provinsi Sumatera Utara*. Karya tulis ilmiah tidak diterbitkan. Medan: Universitas Sumatra Utara.



- Igarashi, Y., Miura, S.S., Fujita, T., Furumai,T. 2006. *Pterocidin, a Cytotoxic Compound from the Endophytic Streptomyces hygroscopicus*. Japan: Pubmed. 59(3):193-5.
- Karyana, M., Burdarm, L., Yeung, S., Kenangalem, E., Wariker, N., Maristela, R., Umana, K.G., Vemuri, R., Okoseray, M.J., Penttinen, P.M., Ebsworth, P., Sugiarto, P., Anstey, N.M., Tjitra, E., Price, R.N. 2008. *Malaria Morbidity in Papua Indonesia, an Area with Multidrug Resistant Plasmodium vivax and Plasmodium falciparum*. Malaria Journal, 7:148 doi:10.1186/1475-2875-7-148. <http://www.malariajournal.com/content/7/1/148>
- Khamna, S., Yokota, A., Lumyong, S. 2008. *Actinomycetes Isolated from Medical Plant Rhizosphere Soil: Diversity and Screening of Antifungal Compounds, indole-3-acetic acid sidorephore Production*. World Journal Microbiology Biotechnology 10:1007.
- Khatib, R.A., Selemiani, M., Mrishoe, G.A., Masanja, I.M., Amuri, M., Njozi, M.H., Kajungu, D., Kuepfer, I., Abdulla, S.M., de Savigny, D. 2013. Access to Artemisinin-based Anti-malarial Treatment and its Related Factors in Rural Tanzania. doi:10.1186/1475-2875-12-155.
- Khuan, A.H.Y.2008. *A Novel Class of Immunoproteasome Catalytic Subunit LMP2 Inhibitor And its Therapeutic Potentials in Cancer*. University of Kentucky.
- Kreindenweiss, A., Kremsner, P.G., Mordmuller, B. 2008. *Comprehensive Study of Proteasome Inhibitors Against Plasmodium falciparum Laboratory Strains and Field Isolates from Gabon*. University of Tübingen, Tübingen, Germany.
- Kublin,J.G.,Dzinjalalamala,F.,Kmwendo,D.D.,Malkin,E.M.Cortese,JF.,Martino,L.M., Mukdam,RA. 2002. *Molecular Markers for Failure of Sufadoxin-Pyrimethamine and Chlorproguanil Dapsone Treatment of Plasmodium falciparum Malaria*. J.Infect.Dis 185:380-88.
- Lister, J. 2013. *Disadvantages & Advantages of an HPLC*. eHow Contributor. http://www.ehow.com/list_5911530_disadvantages-advantages-hplc.html#ixzz2oLPtXRxt.
- Loris,N. 2008. *Rapamycin: The Ocurrence, Bioactivity, Biosynthesis and Synthesis*. Chemistry 150.
- Marinelli, F.2009.*Chapter 2. From Microbial Products to Novel Drugs that Target a Multitude of Disease Indications*. Department of Biotechnology and Molecular Sciences, University of Insubria, Varese, Italy.
- Mc. Cutchan, TF., Piper, RC., Makler, MT. 2008. *Use of Malaria Rapid Diagnostic Test to Identify Plasmodium knowlesi Infection*. Emerging Infectious Diseases 14:11.
- Miyadoh, S. 1993. *Research on Antibiotic Screening in Japan over the Last Decade: A producing Microorganisms Approach*. Actinomycetologica. 9:100–106.
- Mugittu,K., Genton,B., Mshinda,H and Beck HP.2006. *Molecular Monitoring of Plasmodium falciparum Resistance to Artemisinin in Tanzania*. Malaria Journal 5:126

- Nurkanto, A., Listyaningsih, F., Julistiono, H., dan Agusta, A. 2010. *Eksplorasi Keanekaragaman Aktinomisetes Tanah Ternate Sebagai Sumber Antibiotik*. Jurnal Biologi Indonesia 6 (3): 325-39.
- Putra, E.D.L. 2004. *Kromatografi Cair Kinerja Tinggi dalam Bidang Farmasi*. Jurusan Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam. Universitas Sumatera Utara: 1 – 22.
- Riskesdas RI, 2010. *Riskesdas 2010 : Malaria di Indonesia*. Tim Penyakit Menular dan Biomedis, SIMNAS VI, Jakarta.
- Rivo, Y.B., Alkarimah, A., Ramadhani, N.N., Cahyono, A.W., Laksmi, D.A., Winarsih, S., Fitri, L.E. 2013. *Metabolite extract of Streptomyces hygroscopicus Hygroscopicus inhibit the growth of Plasmodium berghei through inhibition of ubiquitin – proteasome system*. Tropical Biomedicine 30(2): 291-300.
- Rohman, A., & Gandjar, I. G. 2007. *Kimia Farmasi Analisis*. Cetakan II. Yogyakarta: Pustaka pelajar. p. 249.
- Rosenthal, P.J. 2003. Review *Antimalarial Drug Discovery: Old and New Approaches*. The Journal of Experimental Biology **206**: 3735-3744 <http://jeb.biologist.org/cgi/reprint/206/21/3735>
- Schmidt, U dan Schmidt, J. 1992. *The Synthesis of eponemycin*. J. Chem. Soc., Chem. Commun, 529-530
- Sharma, H. & Parihar, L. 2010. *Antifungal Activity of Extracts Obtained from Actinomycetes*. Journal of Yeast and Fungal Research 1(10): 197-200.
- Sheperd, M.D., Kharel, M.K., Bosselman, M.a., Rohr, J. 2010. *Laboratory Maintenance of Streptomyces species*. Curr Protoc Microbiol. Doi: 10.1002/9780471729259.mc10e01s18.
- Sin, N., Meng, L., Auth, H. & Crews, C.M. 1998. *Eponemycin Analogues: Syntheses and Use as Probes of Angiogenesis*. Bio- organic and Medicinal Chemistry 6: 1209-17.
- Solanki, R., M.Khanna and R, Lal. 2008. *Bioactive Compound from Marine Actinomycetes*. Indian J. Microbiol., 48:410-431.
- Sulistyaningsih Fitri, L.E., Löscher, T., Berens-Riha, N.. 2010. Diagnostic Difficulties with *Plasmodium knowlesi* Infection in Humans. EID• www.cdc.gov/eid • 16(6):1033-34.
- Tarigan J. 2003. *Kombinasi Kina Tetrasiklin pada Pengobatan Malaria Falciparum tanpa Komplikasi di Daerah Resisten*. Thesis. Universitas Sumatera Utara; Medan, Indonesia. p. 20.
- WHO, 2010^a.*Global Report on Antimalaria Drug Efficacy and Drug Resistance : 2000 – 2010*. Geneva, Switzerland.
- WHO, 2010^b.*Guidelines for The Treatment of Malaria – 2nd Edition*. Geneva, Switzerland.
- WHO, 2012. *World Malaria Report 2012*. Geneva, Switzerland.

Wichman, O., Muelhlberger, N., Jelinek, T., Alifrangis, M., Peyerl, H.G., Muhlen, M., Grobusch, M., Gascon, J., Matteelli, A., Laferl, H., Bisoffi, Zeno., Ehrhardt, S., Cuadros, J., Hatz, C., Gjorup, I., McWhinney, P., Beran, J., da Cunha, S., Schulze, M., Kollatritsch, H., Kern, P., Fry, G., Richter, J., and European Network on Surveillance of Imported Infectious Diseases. 2004. *Screening for Mutation Related To Atovaquone-Proguanil Resistance in Treatment Failures and other Imported Isolates of Plasmodium Falciparum in Europe.* J. Infect Dis. 90:1541-46

Won CY, Balunas MJ, Chai HB, Kinghorn AD. 2006. *Drug Discovery from Natural Sources.* AAPS Journal, 8(2): E239-E253.

Marco, M., & Coterón, J.M. 2012. *Falcipain inhibition as a promising antimalarial target.* Curr Top Med Chem;12(5):408-44

